All In Biotech

Drug Trial Radar · NCT01792310

A Phase 1/2A Study of LAM561 in Adult Patients With Advanced Solid Tumours

A Phase 1/2A Dose Escalation Study of LAM561 in Adult Patients With Advanced Solid Tumours Including Malignant Glioma

Last checked: Nov 19, 2026Latest source record: Feb 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

54

Actual

Start

May 2013

Primary completion

Sep 2016

Study completion Sep 2016

Sponsor

Lead sponsor
Laminar PharmaceuticalsIndustry
Sponsor type
Industry
Collaborators
Specialized Medical Services (SMS)-Oncology BV; Royal Marsden NHS Foundation Trust; Northern Institute for Cancer Research, Newcastle; Vall d'Hebron Institute of Oncology; Instituto Oncológico IMQ, Clínica IMQ Zorrotzaurre. Bilbao; Onkologikoa, San Sebastián.
First posted
Feb 15, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 1/2A, open label, non-randomized study in patients with advanced solid tumours including malignant glioma

Conditions

  • Glioma
  • Other Solid Tumours

Interventions

  • LAM561Drug

    Patients will receive treatment cycles of 21 days, until any criterion for discontinuation (clinical or radiological progression of disease, clinically unacceptable toxicity, or another "general" discontinuation criterion) is met. Patients are expected to receive between one and 6 cycles of treatment. The treatment period may be extended if clinical benefit is shown. In the event of significant GI toxicity, the treatment schedule may be modified from continuous dosing to an intermittent regime In the case of toxicity, the dose of LAM561 may be reduced or delayed by up to 14 days at the discretion of the Investigator. A maximum of two dose reductions will be permitted per patient. Treatment "holidays" of no more than 14 days are also permitted for reasons other than toxicity. Intra-patient dose escalation may be permitted in certain specific circumstances.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of patients with adverse eventsTime frame: From the first dose of study drug until 30 days after the last dose of study drug

Locations

5 sites in 2 countries. Site status is shown where the registry gives one.

  • Vall D'Hebron Institute of Oncology

    Barcelona, Spain

  • Instituto Oncológico IMQ, Clínica IMQ Zorrotzaurre

    Bilbao, Spain

  • Onkologikoa

    San Sebastián, Spain

  • Sir Bobby Robson Cancer Trials Research Centre, The Northern Centre for Cancer Care, Freeman Hospital

    Newcastle, Newcastle Upon Tyne, United Kingdom

  • The Royal Marsden Hospital Drug Development Unit

    Sutton, Surrey, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.